Regulatory Enrolment Process and Common Electronic Submission Gateway Submission

1. Key takeaways

Two electronic steps stand between a manufacturer and the submission of a device dossier to Health Canada: the Regulatory Enrolment Process (REP) completes the enrolment of the company and the products, and the Common Electronic Submission Gateway (CESG) carries the electronic submission of the dossier itself. In practice the two form a sequence — enrol first, then submit — and the sequence is not optional. Enrolment is a precondition for the dossier to enter Health Canada’s processing flow, so the scheduling of the two steps is linked, and a project plan that treats them as independent tracks will misstate the true critical path. Understanding the division of labour between the two systems, and preparing the dossier to the structural expectations of the gateway, are the two decisions that most directly shape how smoothly this stage runs.

• REP covers enrolment of the company and the products; CESG carries the electronic submission of the dossier.
• The practical order is enrol first, submit second; a dossier cannot enter processing before enrolment is complete.
• The names and sequence of the electronic steps are operational practice, not provisions written into the Regulations.
• Directory structure, file naming and file format must conform to the gateway’s requirements, or the dossier is returned at screening.
• Canadian and United States electronic submission tools are separate systems, and dossiers are prepared separately for each.

2. Legal basis

The regulatory anchor for this stage is the Medical Devices Regulations, which govern licence applications; the electronic systems themselves are described in Health Canada’s operational guidance rather than in the Regulations. The table below lists the sources relied on, including the item that reflects industry-side compilation and is labelled accordingly.

3. Expert insights

Insight 1: The names and sequence of the electronic submission steps are operational practice, not provisions of the Regulations.

REP, CESG and the Drugs and Health Products Portal (DHPP) are the names of Health Canada’s electronic tools, and the text of the Regulations does not directly prescribe them. When these systems are cited in a dossier, a submission plan or an internal procedure, the citation should be marked as a practical estimate, and the current Health Canada operational guidance should be treated as the controlling reference. This item is itself a practical estimate compiled from industry practice. The reason for this discipline is straightforward: electronic platforms are renamed, reorganised and re-versioned far more often than regulations are amended, so any document that hard-codes platform names without a caveat will age faster than the process it describes.

Insight 2: The enrol-first, submit-second sequence determines project scheduling.

Until the enrolment step is complete, the dossier cannot enter Health Canada’s processing flow, no matter how finished the dossier itself is. In GRZAN’s Canadian projects, enrolment completion is therefore set as an independent first milestone, separate from dossier preparation. This keeps the dependency visible: if enrolment is delayed, the entire downstream schedule shifts, and no amount of acceleration on the dossier side can recover the time. Treating the two steps as one combined milestone, by contrast, hides the dependency and makes it easy to discover the problem only at the moment of submission, when it is most expensive to fix.

Insight 3: The electronic submission requirements for file structure are rigid.

The directory structure of the dossier, its file naming and its file format must conform to the requirements of the gateway. Where the structure does not conform, the dossier is returned at the screening stage, and the return is unrelated to the technical content of the product. A submission with excellent engineering content can still be bounced for a naming inconsistency, and the reviewer never reaches that engineering content until the structure is accepted. This is the same formal-layer discipline that applies to screening generally: the administrative packaging of the dossier is a deliverable in its own right, with its own verification, and it should not be left as an afterthought once the technical sections are written.

Insight 4: The United States and Canada do not share electronic submission tools.

The United States uses the eSTAR template, which is mandatory for 510(k) and De Novo submissions and is currently at version 7.1; Canada uses its own electronic submission steps. The two systems are not interchangeable, and a dossier cannot simply be reused across them. Each side’s submission must be prepared according to that side’s own requirements, in that side’s own structure and format. Teams working on both markets should budget for genuinely separate preparation work, even where the underlying technical evidence — the testing, the clinical material, the quality system documentation — is common to both filings.

4. Practical recommendations

• Complete the enrolment step before dossier preparation begins; do not wait until the dossier is finished and then enrol as an afterthought.
• Determine the directory structure and file naming from the current Health Canada operational guidance, and do not carry over templates from earlier projects.
• Set enrolment completion as a milestone in its own right, and show it on the project Gantt chart alongside dossier preparation.
• Confirm the MDEL status of the Canadian importer, and align the entity information required for enrolment with that record.
• For projects filed in the United States and Canada in parallel, prepare the dossiers separately and do not copy content directly between them.

5. Verification checklist

• □ The enrolment step has been completed and an enrolment confirmation has been obtained
• □ The dossier directory structure and file naming have been checked against the current operational guidance
• □ The entity information required for enrolment is consistent with the MDEL record
• □ Enrolment completion has been set as an independent milestone in the project Gantt chart
• □ For parallel United States and Canada projects, the dossiers have been prepared separately
• □ REP / CESG has been marked as a practical estimate, with operations governed by current Health Canada guidance

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Canadian market. Our team manages Health Canada Medical Device Licence and MDEL applications, prepares risk-classified dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com